207_Combined course Presentations

Take Home Message (Anaplastic gliomas)

A) 1p/19q CODELETED TUMORS

 Median survival >10 years  Benefit from “upfront” sequential RT and CT (PCV regimen)  RT  PCV or PCV  RT are both feasible options  TMZ instead of PCV? No final answer so far (waiting for results from CODEL trial)

B) NON-CODELETED TUMORS

 Median survival 2-7 years  RT as current standard for newly diagnosed cases.  Benefit from adjuvant TMZ (CATNON trial)